Skip to main content

Table 3 Overall survival in the total entire population and subgroups

From: Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients’ quality of life

    Overall survival  
  Number Median (months)  
  A B A B P value  
All patients 58 36 20.2 11.9 0.001  
Age 69 38 20 19.7 12.9 0.061 NS
  >70 20 16 20.4 8.6 0.001  
Sex: male 36 20 20.4 6.3 0.001  
Sex: female 22 16 19.8 12.6 0.094 NS
T1–2 11 9 36.6 20.5 0.086 NS
T3–4 47 27 15.6 9.4 0.000  
N0 27 15 21.3 13.0 0.007  
N1 31 21 13.6 7.0 0.017  
R0 43 28 20.7 12.5 0.001  
R1 15 8 13.4 5.5 0.034  
Stage 0–IIA 29 13 23.7 15.4 0.008  
Stage IIB–IV 29 23 13.4 7.0 0.043  
  1. NS no significant difference.